A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors

Trial ID # NCT01633970
Phase Ib
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Atezolizumab, Bevacizumab
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, OS, evaluated per RECIST


ORR: 15% (3PR, n=20)
DCR: 55% (3PR, 8SD, n=20)
PFS: 4.9 months (1.2-20.2)
OS: 10.2 months (1.2-26.6)

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: overall (35%)


Bevacizumab+atezolizumab induces durable responses and/or disease stabilization in some patients with platinum-resistant ovarian cancer; the safety profiles are consistent with those of each agent


Moroney JW et al. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res (2020) 26(21):5631-5637

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.